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Ullrich congenital muscular dystrophy is a rather severe type of congenital 
muscular dystrophy with early onset features related to motor development. 
In general it is inherited in autosomal recessive principles, however in the 
Western world mostly seen with  de novo dominant mutations in the collagen 
VI genes. Milder form of the condition is the Bethlem myopathy. There may be 
overlap forms in the clinic resembling the Ehler-Danlos syndrome. There has 
been some radical efforts for cure especially through the apoptosis cascades.
Key words: Ullrich congenital muscular dystrophy, collgen VI genes, Bethlem 
myopathy, autophagy.
Introduction
Historical note and nomenclature
In 1930, Ullrich described a peculiar form of congenital muscular dystrophy 
(CMD) with an unusual combination of distal hyperextensibility and proximal 
contractures in two boys under the name of “congenital atonic-sclerotic muscular 
dystrophy” (1,2). Additional clinical findings were onset in the neonatal period or 
early infancy, generalized muscle weakness, hyperhydrosis, high-arched palate, 
protruded calcanei and normal intelligence. Other CMD patients with a similar 
clinical presentation confirmed the existence of this condition which was named 
“Ullrich disease”. Ullrich phenotype is now classified as a nosologically distinct 
group within the congenital muscular dystrophies, as a subtype of merosin-positive 
congenital muscular dystrophy (1,2).Ullrich congenital muscular dystrophy, UCMD; 
Mendelian Inheritance in Man (MIM) 254090 and Bethlem myopathy, BM; MIM 
158810, were originally described as seperate entities but demonstration of collagen 
VI gene mutations led to the concept of ‘collagen VI-related myopathies’ as a group 
of conditions covering a broad clinical spectrum (3).
Clinical manifestations
The signature clinical feature of the Ullrich congenital muscular dystrophy 
phenotype is congenital muscle weakness with proximal joint contractures and 
coexisting marked distal joint hyperlaxity. 100th ENMC International Workshop 
diagnostic criteria for Ullrich CMD due to primary collagen type VI involvement 
are summarized in Table 1 (4, 5). 
Hypotonia, congenital hip dislocation, congenital torticollis, contractures, 
arthrogrypozis and distal laxity may be the neonatal findings. Notably most of the 
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patients have delayed motor milestones and generalized 
slowly progressive muscle weakness including mild 
facial weakness and high-arched palate. Contractures 
of proximal joints, particularly elbows and knees are 
frequently present from birth. Distal joints of hands, 
ankles, toes and finger joints are hyperextensible 
lifelong. During the early follow-up most contractures 
release spontaneously and some return over the years, 
particularly involving elbows, knees and spinal joints. 
Patients usually have dry skin and protruded bulbs of 
hair follicles giving the appearance of dermatitis. There 
may be excessive cheloid formation at the sites of 
muscle biopsy. Protruded calcaneus and thickening of 
the subcutaneous tissue on the soles of the feet may be 
the additional key features. There is absence of severe 
mental retardation. Cases of variable severity have been 
described; the most severe end of the disease is the 
sclerotic form with severe contractures and rigidity of 
the spine (6)(Fig.1). Although the patients at the severe 
end of the spectrum never achieve independent walking, 
there are also patients with a more benign presentation 
who can walk independently. 
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• Autosomal recessive inheritance
• Neonatal features may include hypotonia, hip dislocation, contractures and distal laxity
• Delayed motor milestones
• Generalized slowly progressive muscle weakness including mild facial muscles and 
high-arched palate
• Distal laxity (hand, foot, and finger)
• Contracture of proximal joints: torticollis, limited neck flexion, and kyphoscoliosis
• Protruded calcaneous 
• A proportion of patients who never achieved the ability to walk
• Early respiratory failure
• No central nervous system involvement with normal intelligence
• Serum CK: normal or mildly elevated 
• Muscle pathology varies from myopathic to dystrophic, with fiber size variation, 
interstitial fibrosis and may include necrotic and regenerating process
• Collagen VI staining: complete to partial deficiency 
• The diagnosis can be confirmed by COL6 genes mutations 
Table1. Diagnostic criteria for Ullrich CMD due to primary collagen type VI involvement
Etiology
This is a collagen VI related disorder. In a series of 15 
patients (5), 11 had muscle biopsy samples for collagen 
VI immunostaining and 5 had a marked reduction, 1 
had a mild reduction and 5 had normal expression, 
whereas linkage analysis in 6 families linked with 
COL6A1, COL6A2 and COL6A3. As a result primary 
collagen VI involvement was 40% (6/15).  According to 
our experience including 24 patients from 21 families, 
primary collagen VI involvement with muscle biopsy 
and /or genetic studies is 70% (7). The role of collagen 
VI is excluded in the remaining patients with Ullrich 
phenotype, indicating genetic heterogeneity. Further 
analysis of tissue samples of this group is necessary for 
collagen VI expression. In most of the patients, there is 
variable deficiency of collagen VI at the basal lamina 
with an apparently preserved expression in the interstitial 
connective tissue, whereas a minority of the patients 
show complete deficiency in the protein (8). 
Pathogenesis and Pathophysiology
Collagen type VI is a ubiquitous connective tissue 
component, present primarily in the stroma and also 
close to the basement membrane of most tissues (9,10). It 
is a glycoprotein that consists of three seperate chains, 
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the 1, 2 and 3 collagen chains, encoded by the COL6A1, 
COL6A2 (11), and COL6A3 genes, respectively. The 1 
and 2 collagen chains are similar in size (140kDa) and 
their genes are linked in a head-to-tail orientation on 
chromosome 21q22.3 (8). The 3 collagen chain is much 
larger (260-330 kDa) and is encoded by the gene located 
on chromosome 2q37 (8). The three chains share the 
same core structure: a relatively short triple helical 
domain of 335-336 aminoacids with repeating Gly-Xaa-
Yaa aminoacid sequences flanked by globular domains 
made up of motifs of 200 aminoacids each that are 
homologous to von Willebrand factor type A domains 
(12,13,14). The three chains fold into triple-helical 
monomers, which are then assembled in an antiparallel 
manner into dimers with the N-terminal globular 
domains protruding (12,15). The dimers associate 
laterally into tetramers, which are subsequently secreted 
into the extracellular space and associate, end-to-end, 
into double-beaded collagen VI microfibrils that are 
characterized by a band of perodicity of 100 nm. 
Collagen type VI is distributed in the connective tissues 
and is particularly abundant around cells, associated 
with interstitial collagen fibres types I-III, with a possible 
role as substrate for the attachment of cells and in 
anchoring collagen fibres, nerves and blood vessels to 
the surrounding connective tissue (16,1).   
Collagen VI genes were first found to be associated with 
Bethlem myopathy indicating tissue-specific importance 
of collagen VI (17) identified compound heterozygosity 
in the COL6A2 gene and complete deficiency of collagen 
VI by immunohistochemistry in the muscle biopsy. 
Expression of collagen IV, a major component of the 
basal lamina was normal. Electron microscopy showed a 
total absence of microfibrils, which are usually seen in 
the interstitium associated with collagen fibrils. The 
authors suggested that loss of anchoring between the 
basal lamina and the interstitium may be the molecular 
mechanism of muscular dystrophy.  Collagen VI 
mutations in UCMD reported to date are extremely 
heterogenous. It was known that recessive mutations in 
COL6A2 and COL6A3 genes result in Ullrich CMD 
(17, 18, 19, 20, 21) whereas dominant mutations in all 
three collagen genes have been associated with Bethlem 
myopathy (OMIM # 158810) (21, 22, 23), a milder 
childhood-onset disorder characterized by muscle 
weakness and later manifesting multiple joint 
contractures (24, 25). In three families, a form of 
autosomal dominant limb girdle muscular dystrophy has 
also been attributed to heterozygous mutations in the 
COL6A1 and COL6A2 genes (26). All of the COL6A2 
mutations described in UCMD so far lead to translational 
frameshifts and subsequent premature stop codons (17, 
18, 19). In two of these patients with UCMD, the 
COL6A2 mRNA has been shown to be nearly absent 
because of nonsense-mediated mRNA decay (27). 
Nonsense-mediated mRNA (NMD) decay is briefly an 
mRNA quality-control mechanism that degrades 
aberrant mRNAs containing premature translation 
termination codons. In a recent study the effects of NMD 
inhibition on the phenotype of Ullrich disease is 
evaluated (28). The patient studied showed a homozygous 
frameshift mutation with a premature translation 
termination codon in the collagen VI 2 gene, which 
encodes a truncated but partially functional protein. 
Fibroblast culture showed nearly complete loss of the 
triple-helical collagen VI protein and functional defects 
in the extracellular matrix. Knockdown of essential 
proteins for NMD causes the up-regulation of the mutant 
triple-helical collagen VI, resulting in the formation of 
partially functional extracellular matrix. The authors 
suggest also that inhibition of NMD may be a therapeutic 
approach (28, 29). Of the three COL6A3 homozygous 
mutations in UCMD, two are nonsense mutations-one in 
the N-terminal globular domain and one in the triple-
helical domain-and third one leads to skipping of an 
exon encoding the triple-helical domain (20). The 
patients with COL6A3 gene mutations exhibited 
complete or partial deficiency of collagen VI protein in 
the muscle. All of the mutations defined so far are 
documented in a recent review (30). In two patients, one 
with a classical severe phenotype of UCMD and the 
other with distal joint hyperlaxity in the absence of 
contractures who carry de novo heterozygous in-frame 
deletions of different sizes and locations in the triple-
helical domain of the COL6A1 mRNA were defined 
(23). This provides a biochemical and immuno-
histochemical evidence for a genotype/phenotype 
correlation and show that the severe UCMD phenotype 
can arise from a heterozygous mutation in collagen VI 
through a dominant negative mechanism. With this 
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challenge, additional patients from different groups were 
reported with dominant collagen VI mutations. Three of 
the five patients with a clinical diagnosis of Ullrich CMD 
had heterozygous in-frame deletion in N terminal region 
of the triple helical domain. Protein biosynthesis and 
assembly studies showed that these mutations act in a 
dominant negative fashion and result in severe collagen 
VI matrix deficiencies. These findings also show that 
dominant mutations are common in Ullrich CMD (11, 
30, 31, 32). Biosynthetic consequences of the mutations 
depend on their positions in the triple-helical domain 
(33, 34). It is not clear what molecule anchors the 
collagen VI network to the basement membrane. Possible 
candidates are collagen type IV, perlecan and fibronectin 
which are present in the basement membrane and interact 
with collagen VI in vitro (35). These results all indicate 
a critical role of collagen VI in the muscle basement 
membrane and suggest that mislocalization of collagen 
VI is a potential mechanism for the severe UCMD 
phenotype.  Pace et al studied effects of collagen VI 
glycine mutations on spectrum of clinical severity. Eight 
newly diagnosed patients with different clinical severity 
were screened for three collagen VI messenger RNA for 
mutations, collagen VI biosynthesis and assembly 
pathway (36). All of the patients had heterozygous 
glycine mutations toward the N-terminal end of the triple 
helix. There were two assembly phenotypes. In the first 
group collagen VI dimers accumulated in the cell but not 
the medium, microfibril formation in the medium was 
moderately reduced and amount of collagen VI in the 
extracellular matrix was not significantly altered. In the 
second group, a more severe assembly defect leads to 
reduced collagen VI in the extracellular matrix due to 
impaired microfibril formation in the medium due to 
defective disulfide bonding of the secreted collagen VI 
tetramers (36). This study demonstrated that collagen VI 
glycine mutations impair the assembly pathway in 
different ways and disease severity correlates with the 
assembly abnormality (36, 37).  Further evidence 
showed that exon skipping mutations in Collagen VI are 
common and are predictive for severity and inheritance 
(38). Location of the skipped exon relative to the 
molecular structure of the collagen chain strongly 
correlates with the clinical phenotype. As a general 
conclusion, de novo dominant mutations in severe 
UCMD occur relatively frequently in all three collagen 
VI chains and severity of the phenotype depends on the 
ability of mutant chains to be incorporated in the 
multimeric structure of collagen VI (38).  Autosomal 
recessive inheritance of classic Bethlem myopathy have 
also been reported (39, 40). Either recessive or dominant 
mutations causing both Ullrich CMD and Bethlem 
myopathy have relevant implications for genetic 
counseling and genotype-phenotype correlations in 
collagen VI-related myopathies(25).  As a summary, two 
mutational mechanisms are known to underlie UCMD: 
heterozygous dominant negatively-acting mutations and 
recessively-acting loss-of-function mutations.  Large 
genomic deletions are described for the first time in two 
families with UCMD (41). Authors report in detail that, 
this type of a mutation will not be detected by single-
exon amplification and sequencing (unless done 
quantitatively) and a hemizygous change detected on a 
nondeleted allele will appear homozygous, and obscure 
the true genotype of the patient’s disease. on the other 
hand, clinically unaffected parents carrying large 
genomic deletions of COL6A1 and COL6A2 also 
provide evidence that haploinsufficiency for COL6A1 
and COL6A2 is not a disease mechanism for Bethlem 
myopathy (41). These results have great translational 
importance and therapeutic strategies directed at the 
elimination of a dominant negatively-acting mutation 
are conceivable and would create a functional state of 
haploinsufficiency. There are still patients with UCMD 
phenotype and normal collagen VI expression on the 
muscle biopsy and/or not linked to known collagen VI 
loci indicating genetic heterogeneity of this condition (5, 
7). Clinical and morphological phenotype of 15 Ullrich 
CMD patients from 11 consanguineous families showing 
potential linkage either to 21 q22.3 (6 families) or to 
2q37 (5 families) was evaluated. The clinical phenotype 
of the patients with complete collagen VI deficiency in 
muscle or cultured fibroblasts was severe compared to 
the partial deficiencies with a milder presentation. There 
was no significant phenotypical difference between the 
families linked to each of the 2 loci. The authors suggest 
that there may be a correlation between clinical severity 
and degree of collagen VI deficiency (42).  Genotype-
phenotype correlation is reported for the first time in a 
study including five Ullrich CMD patients. It is 
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demonstrated that heterozygous glycine substitutions in 
the triple helix domain of COL6A1 are dominant and 
results in a milder phenotype whereas recessive 
mutations result in more severe clinical and biochemical 
phenotypes (43).  In an Ullrich CMD patient on the 
severe end of the spectrum, reverse-transcription-PCR 
analysis of fibroblast RNA suggested a heterozygous in 
frame deletion of exon 13 in the triple helical domain of 
COL6A2. This dominantly acting mutation activated 
numerous cryptic splice acceptor sites and generated 
normal and exon-13 deleted COL6A2 mRNA, and 
multiple aberrant transcripts containing frameshifts that 
were degraded through a nonsense-mediated decay. 
Decreased m RNA expression was defined as the primary 
pathogenic mechanism in this unique patient (44). The 
algorithm of molecular work-up clearly shows that 
complete analysis is essential to make genotype-
phenotype correlations.  Pepe, et al identified highly 
similar heterozygous COL6A1 genomic deletions in two 
patients with UCMD and the milder Bethlem myopathy. 
The 5’ breakpoints of both deletions are located within a 
minisatellite in intron 8 (45,32). The mutations cause in-
frame deletions in the amino-terminus of the triple-
helical domain. Although the biosynthetic consequences 
of the mutations are similar, there are differences in the 
clinical presentations of the patients due to modifying 
factors. The authors demonstrate the presence of a 
minisatellite in COL6A1 intron 8 predisposing the 
defined area to multiexon deletions in collagen VI-
related muscular dystrophies. Genomic DNA analysis 
and short-range RT-PCR may underestimate the 
multiexon deletions so long distance RT-PCR and 
protein analyses are necessary for the accurate molecular 
diagnosis (32). Genetic and clinical correlations in early 
onset collagen VI myopathies (UCMD, Bethlem 
myopathy and intermediate phenotypes) have been 
reported recently, in a muticenter study (46). The authors 
characterized, at the clinical, cellular and molecular 
levels, 49 patients with onset in the first 2 years of life. 
Patients were classified into 3 groups: early severe 
(18%), moderate-progressive (53%), and mild (29%). In 
this study, ColVI secretion was analyzed in skin 
fibroblasts. Chain-specific transcript levels were 
quantified by quantitative reverse transcriptase 
polymerase chain reaction, and mutation analysis was 
performed by sequencing of complementary DNA. As a 
result, ColVI secretion was altered in all fibroblast 
cultures studied and 56 mutations mostly novel and 
private were detected. Dominant de novo mutations 
constituted 61% of cases and mutations causing 
premature termination codons (PTCs) or in-frame 
insertions strikingly destabilized the corresponding 
transcripts. Homozygous PTC-causing mutations in the 
triple helix domains led to the most severe phenotypes 
(ambulation never achieved) and dominant de novo in-
frame exon skipping and glycine missense mutations 
were identified in patients of the moderate-progressive 
group (loss of ambulation). Quantitative RT-PCR is 
defined as a helpful tool for identification of some 
mutations (46).    As a whole, patients with a phenotype 
consistent with Ullrich CMD constitute the largest group 
of patients with merosin-positive congenital muscular 
dystrophy. Since direct molecular analysis of the COL6 
genes is complex, a reliable test at the protein level is 
required to guide molecular analysis. In a recent study 
from the Hammersmith’s group, it is documented that 
immunohistochemical analysis of skin biopsies may not 
always reveal an underlying collagen VI defect and 
analysis of collagen VI synthesis and deposition in skin 
fibroblast cultures is a useful technique (47). Collagen 
VI expression is analyzed in 14 patients with Ullrich 
CMD, and analysis of collagen VI in fibroblast cultures 
from eight of these patients showed reduced extracellular 
deposition in all cases and intracellular collagen VI 
staining in seven cases. Collagen VI immunolabelling 
was reduced in all the available muscle biopsies (n=7). 
Collagen VI status was also evaluated from the skin 
(n=10) and fibroblast cultures (n=8) and even in patients 
with normal collagen VI expression in skin (n=5), 
collagen VI was reduced in the extracellular matrix with 
varying degrees of intracellular labeling. There was no 
correlation between the extent of the reduction in the 
muscle and fibroblast cultures, the mode of inheritance 
and the severity of the clinical phenotype. Recently, the 
role of confocal microscopy and rotary-shadowing 
electron microscopy (REM) is reported to be useful to 
identify a secondary collagen VI defect (48). In a patient 
with Ullrich CMD, the authors described mildly reduced 
colllagen VI immunolabeling around myofibers and 
significantly decreased collagen IV-VI co-localization in 
Ullrich Congenital Muscular Dystrophy  
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basal lamina and several capillaries despite normal 
collagen VI staining in the muscle biopsy. The 
characteristic abnormality with selective reduction of 
collagen VI microfilaments at the level of the reticular 
lamina of the basal membrane reinforces the idea that 
other proteins closely interacting with collagen VI may 
be also implicated in the pathogenesis. By these means, 
extensive morphological analysis by confocal imaging 
and REM may be useful methods to predict Ullrich 
CMD patients with secondary collagen VI defects. 
Selective depletion of collagen VI in the muscle basal 
lamina compared to  normal levels in the endomysium is 
not clear. Collagen microfibrils near the surface of 
muscle cells are reduced in patients with UCMD (17,49), 
and interactions of collagen VI near the cell surface may 
be more sensitive to structural changes and/or less stable 
than the interactions with extracellular matrix proteins 
leading to mislocalization of collagen VI. Collagen VI 
turnover is regulated by signaling through integrins and 
as an additional mechanism impaired binding between 
mutated collagen and VI and integrins may alter collagen 
composition of the basement membrane and endomysial 
connective tissue (50). Synthesis, formation and binding 
of collagen VI to the extracellular matrix was studied 
from fibroblast samples with p.G284R mutation in 
COL6A1 and showed decreased binding of collagen VI 
microfibrils to extracellular matrix resulting in 
sarcolemma-specific collagen VI deficiency (51). 
Secretion and assembly of type IV and VI collagens is 
demonstrated to depend on glycosylation of 
hydroxylysines which are shown to be indispensable for 
the formation of basement membranes (52).     Skin 
abnormalities, including predisposition to keratosis 
pilaris and abnormal scarring were desribed in UCMD 
and Bethlem myopathy patients. COL6A5, previously 
designated as COL29A1 was linked to atopic dermatitis. 
To gain insight into the function of these two new chains, 
the authors studied expression of the collagen VI a5 and 
a6 chains in normal human skin and skin of patients with 
collagen VI-related myopathies. They showed that 
localization of a5 and to a lesser extent a6 is restricted to 
the papillary dermis, where the protein mainly colocalizes 
with collagen fibrils (53). In UCMD patients with 
COL6A1 and COL6A2 mutations, immunolabeling for 
a5 and a6 was often altered, whereas in a UCMD and 
Bethlem myopathy patient with COL6A3 mutation, 
expression was unaffected, suggesting that these chains 
may substitute for a3, while forming heterotrimers.   A 
dystrophic mouse model where collagen VI synthesis 
was prevented by genetic ablation of the Col6a1 gene 
allowed investigation of pathogenesis, which revealed 
the existence of a calcium-mediated dysfunction of 
mitochondria and the sarcoplasmic reticulum (54). 
Critical point appears to be inappropriate opening of the 
mitochondrial permeability transition pore (PTP), an 
inner membrane high conductance channel. Studies 
from fibroblasts of patients with UCMD and Bethlem 
myopathy showed the existence of a latent mitochondrial 
dysfunction irrespective of the genetic background (55). 
PTP opening seems to be final common pathway for 
skeletal muscle fiber death (56). On the other hand, 
mitochondrial ultrastructural alterations are observed in 
many forms of muscle pathology; myofibers with 
mitochondrial-sarcoplasmic reticulum alterations 
display nuclear features of apoptosis, and whether these 
findings are cause or consequence should be evaluated 
with caution.  Defective activation of the autophagic 
machinery is described to be pathogenic first, in the 
skeletal muscles of collagen VI-knockout mice, and than 
muscle biopsies from subjects with Bethlem myopathy 
or UCMD (57). Persistence of abnormal organelles and 
apoptosis are caused by defective autophagy.
Epidemiology 
There is no epidemiological study in our population, 
but to our experience about 20% of our patients with 
merosin positive congenital muscular dystrophy have 
UCMD phenotype.    A detailed population study 
of patients with genetic muscle disease in northern 
region of England, including over 1100 patients with 
molecularly characterized 31 muscle entities showed 
that for the group of congenital muscular dystrophies 
point prevalence was 0.89/100000 and Ullrich CMD and 
Bethlem myopathy have a prevalence of 0.13/100000 
and 0.77/100000, respectively (58). This study for the 
first time presents epidemiological information for 
collagen VI related disorders.  
Ullrich Congenital Muscular Dystrophy  
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Prevention 
Pattern recognition for clinical diagnosis and pedigree 
information is essential. Genetic counselling could be 
provided by collagen VI immunohistochemistry of 
chorion villus sample. By using both haplotype analysis 
of DNA extracted from chorionic villus samples and 
collagen VI immunocytochemistry, prenatal diagnosis 
of Ullrich CMD is possible. In a consanguineous 
family with linkage to COL6A3 locus and negative 
immunostaining with collagen VI in the proband’s 
muscle tissue, haplotype analysis in combination with 
immunocytochemistry is presented as a rapid and a 
reliable method (59).  Genetic counseling in Ullrich 
CMD may be complex in families with homozygous 
or compound heterozygous null mutations in COL6A1, 
COL6A2 and COL6A3 (60).    Based on findings of 
increased occurrence of spontaneous apoptosis and 
latent mitochondrial dysfunction in myoblasts of patients 
with Ullrich CMD, pharmacological therapy with 
cyclosporine A and methylAla3ethylVal4cyclosporin 
in five patients with Ullrich CMD is reported and 
was demonstrated to prevent oligomycin-dependent 
mitochondrial depolarization in cells from Ullrich CMD 
patients (61). This study is presented by the authors as an 
essential step toward a pharmacological therapy. There 
is still a need for development of alternative outcome 
measures or biomarkers using different platforms such 
as genomics and proteomics, since randomized clinical 
trials are not feasible for this rare disorders (62).  In the 
Col6a1-/- myopathic mice model, inactivation of the 
gene encoding for cyclophilin D was shown to rescue 
mitochondrial dysfunction and ultrastructural defects, 
and normalized incidence of apoptosis (63). The authors 
demonstrated that a) lack of cyclophilin D is equivalent 
to its inhibition with cyclosporin A at curing the mouse 
dystrophic phenotype, b) establish a cause-effect 
relationship between cyclophilin dependent permeability 
transition pore regulation and c) validate cyclophilin D 
and permeability transition pore as pharmacological 
targets for the therapy of human ColVI myopathies. 
Therapeutic effects of cyclophilin inhibitor Debio 025, 
a selective cyclophilin inhibitor, have been studied in 
Col6a1-/- myopathic mice (64). Debio 025 did not inhibit 
calcineurin activity, it desensitizes the mitochondrial 
permeability transition pore in vivo. Selective inhibition 
of matrix cyclophilin D without inhibition of calcineurin, 
prevented the mitochondrial dysfunction and normalized 
the apoptotic rates and ultrastructural lesions. The authors 
suggest that collagen VI-related muscular dystrophies 
can be potentially treated with Debio 025 which does 
not expose patients to potential harmful effects of 
immunosupression (64).    Knockout mice has a mild 
motor phenotype and progress is hindered in part by 
lack of an adequate animal model for UCMD. Recently, 
zebrafish models of collagen VI-related myopathies are 
generated using antisense morpholino technology (64). 
Morpholinos designed to exon 9 of col6a1 produced 
a severe muscle disease reminiscent of UCMD, while 
ones to exon 13 produced a milder phenotype similar 
to Bethlem myopathy. This is the first vertebrate model 
with a severe phenotype resembling UCMD and 
zebrafish embryos with dominant-negative  transcripts 
of col6a1 result in severe morphologic, structural and 
functional changes. Cyclosporin A improved motor 
deficits in UCMD-like zebrafish, but failed to reverse the 
sarcolemmal membrane damage (65).       
Differential diagnosis
Differential diagnosis is required with the rigid spine 
syndrome, merosin positive congenital muscular 
dystrophy, some forms of Ehler-Danlos syndrome, 
congenital laxity of the ligaments and connective 
tissue diseases.  Furthermore, electron microscopy 
of the skin biopsies from patients with Ullrich CMD 
revealed ultrastructural abnormalities including 
alteration of collagen fibril morphology and increase 
in ground substance, which resemble findings in Ehler-
Danlos syndrome. These findings suggest that there 
is true connective tissue component as part of the 
phenotypic spectrum of Ullrich CMD. There seems to 
be a clinical and morphological overlap between these 
two groups of disorders (66). Recently, in the French-
Canadian population a new form of CMD with joint 
hyperlaxity and proximal contractures with a milder 
phenotype compared to UCMD, is defined and mapped 
to chromosome 3p23-21 (67). Pathological and genetic 
studies excluded mutations in collagen VI subunits. 
All patients are from the southwestern part of Quebec, 
suggesting a new French-Canadian founder effect.  
Ullrich Congenital Muscular Dystrophy  
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involvement of the gastrocnemii. Muscle biopsy shows 
myopathic and/or dystrophic changes with a positive 
staining for merosin. There is total or partial absence of 
Collagen VI immunostaining in muscle and fibroblast 
tissue in most of the patients. There are two modes of 
collagen VI deficiency based on immunohistochemistry: 
complete deficiency and sarcolemma-specific collagen 
VI deficiency (collagen VI is present in the interstitium 
but is barely detectable in the sarcolemma). Binding 
ability of mutated collagen VI to extracellular 
matrix was markedly reduced and this indicates that 
heterozygous mutations in COL6 genes diminish the 
anchorage of collagen VI micrfibrils to the extracellular 
matrix surrounding myocytes (71). Very small muscle 
fibers in the patients with Ullrich CMD showed marked 
expression of desmin, neural cell adhesion molecule and 
neonatal myosin heavy chain, which is a characteristic 
finding of regenerating fibers, however, they showed 
poor expression of developmental myosin heavy chain 
and thrombomodulin. These additional findings suggest 
that abnormal regeneration or maturation processes 
are involved in the pathogenesis of dystrophic muscle 
changes in the advanced stages (72). Schessl et al studied 
early histological changes in muscle of patients with 
molecularly confirmed UCMD (73). Muscle biopsies 
from 8 UCMD patients with an age from 6 to 30 months 
were studied. Type I fiber atrophy and predominance 
were seen in the  early stages of the disease, with a 
widening of fiber diameter. There were no dystrophic 
changes. A subpopulation of more severely atrophic 
type I fibers was present in one patient, fullfilling the 
diagnostic criteria fiber type disproportion. Early in the 
disease UCMD presents as a non-dystrophic myopathy 
with predominant fiber atrophy (73). Genetic studies 
including linkage and mutation analysis may further 
help to define COL6 gene mutations. It is also important 
to remember that there may be patients with an Ullrich 
CMD phenotype without a primary COL6 involvement. 
A method for rapid direct sequence analysis of all 107 
coding exons of the COL6 genes using single condition 
amplification/internal primer (SCAIP) sequencing is 
described recently (30). Seventy-nine patients with 
Ullrich CMD or Bethlem myopathy phenotype was 
studied and putative mutations in one of the COL6 
genes was found in 62% of the patients. This more 
Diagnostic work-up
Diagnosis of Ullrich congenital muscular dystrophy 
is made on clinical grounds. The major features of the 
disease can be summarized as congenital muscular 
dystrophy with proximal contractures and distal laxity, 
with presentation usually in early infancy with neonatal 
hypotonia, congenital hip dislocation and torticollis. 
Additional key findings include a characteristic facial 
appearance, skin features, protruded calcanei and 
thickening of the subcutaneous tissue on the soles of the 
feet and absence of severe mental retardation. Serum 
creatine kinase levels may be normal or mildly elevated. 
An anteroposterior pelvic X-ray may be helpful to 
denmonstrate hip dislocation. Electromyography is 
useless. Magnetic resonance imaging of the thigh 
muscles may show a selective involvement that is 
relative sparing of sartorious, gracilis, adductor longus 
and rectus (68). In a recent work, nineteen patients with 
genetically proven collagen VI related disorders, 10 
with Bethlem myopathy and 9 with Ullrich CMD were 
evaluated with muscle MRI At the thigh level, in patients 
with Bethlem myopathy, the vasti muscles appeared to 
be the most frequently and most strikingly affected thigh 
muscles with a rim of abnormal signal at the periphery 
of each muscle and relative sparing of the central part. 
The presence of a peculiar involvement of the rectus 
femoris with a central area of abnormal signal within 
the muscle was another frequent finding. Patients with 
Ullrich CMD had a more diffuse involvement of the 
thigh muscles with relative sparing of sartorious, gracilis 
and adductor longus. At the calf level a significant 
proportion of the patients had a rim of abnormal signal 
at the periphery of soleus and gastrocnemii. The authors 
suggest that muscle MRI may be used as an additional 
tool for collagen VI related disorders (69). Muscle MRI 
findings are also reported to be highly suggestive to 
identify specific patterns of involvement in muscular 
dystrophies with rigidity of spine (70).  At the thigh and 
calf muscles levels respectively, UCMD is characterized 
by diffuse involvement with selective relative sparing of 
the anteromedial muscles and more diffuse changes than 
in Bethlem myopathy but similar peripheral involvement 
of the gastrocnemii, and Bethlem myopathy is 
characterized by peripheral involvement more obvious 
in vasti and internal signal in the rectus and peripheral 
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milestones and can walk independently for years. 
There is no correlation between the severity of motor 
impairment, age at onset of the symptoms, histologic 
findings and collagen VI status on muscle biopsy and 
the severity of secondary complications (5, 7). Failure 
to thrive, early tendency to recurrent respiratory tract 
infections, spine deformities, painful dislocated hip may 
be the complications. Mercuri et al reported that failure 
to thrive became more evident after age 10 and 5 of their 
patients required gastrostomy(5,68,69,70). Forced vital 
capacity was always below 40% in all patients aged 5 
years and older, 9 out of 15 patients required nocturnal 
ventilation and 5 of them also required scoliosis surgery. 
Echocardiography was normal in 7 of 154 patients, 
one of their patients with partial absence of Collagen 
VI died unexpectedly at age 12 years, bringing up the 
possibility of sudden electromechanical dissociation. 
Natural history of Ullrich CMD has been reported in a 
cohort of 13 patients followed up in a single center (75). 
Patients aged 15 years or older at last clinical attendance, 
who have long-term longitudinal follow-up data were 
included and compared with patients who were born 
in the same period and died, to better demonstrate the 
course of the disease. Diagnosis depends on clinical 
grounds and genetic confirmation of Col6 mutations. 
than doubles the number of identified COL6 mutations. 
Some patients showed changes in more than one of the 
COL6 genes so some of the Ullrich CMD patients may 
have dominantly acting mutations rather than recessive 
disease. The authors generated a large number of single 
nucleotide polymorphisms with this method which may 
be important in describing phenotypic variability seen in 
collagen VI related disorders (30). Quantitative RT-PCR 
(46) and a novel custom oligonucleotide CGH array 
designed to explore allelic and genetic heterogeneity in 
collagen VI-related myopathies (74) have been described 
as complementary diagnostic tools. By the use of second 
method, a pure intronic mutation in COL6A genes is 
identified for the first time and authors suggested using 
this technology especially in recessive forms of disease, 




Ullrich congenital muscular dystrophy is usually a 
slowly progressive disease. The clinical features and 
prognosis of the patients vary from each other, there are 
patients who never achieve independent walking usually 
in the sclerotic form, at the severe end of the spectrum 
and there are also patients who had mild delay in motor 
Ullrich Congenital Muscular Dystrophy  
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there is no defined complication due to anesthesia in 
five patients with UCMD phenotype who underwent 
scoliosis surgery (5). 
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